Eli Lilly and Company (NYSE:LLY) Shares Sold by West Oak Capital LLC

West Oak Capital LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 12.8% during the third quarter, Holdings Channel reports. The institutional investor owned 5,842 shares of the company’s stock after selling 855 shares during the period. Eli Lilly and Company comprises approximately 1.0% of West Oak Capital LLC’s investment portfolio, making the stock its 8th biggest position. West Oak Capital LLC’s holdings in Eli Lilly and Company were worth $5,176,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. First Community Trust NA increased its stake in Eli Lilly and Company by 390.0% during the 1st quarter. First Community Trust NA now owns 245 shares of the company’s stock worth $191,000 after acquiring an additional 195 shares during the period. Gunderson Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Gunderson Capital Management Inc. now owns 19,905 shares of the company’s stock worth $15,485,000 after purchasing an additional 1,247 shares in the last quarter. BTC Capital Management Inc. bought a new position in shares of Eli Lilly and Company in the first quarter worth $1,432,000. PFW Advisors LLC raised its stake in Eli Lilly and Company by 1.7% in the first quarter. PFW Advisors LLC now owns 982 shares of the company’s stock valued at $764,000 after purchasing an additional 16 shares in the last quarter. Finally, Allied Investment Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $209,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $917.86 on Friday. The stock has a market cap of $872.34 billion, a price-to-earnings ratio of 135.18, a P/E/G ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The company’s fifty day moving average is $921.21 and its 200 day moving average is $857.37. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Sell-side analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on LLY. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a report on Thursday. They issued an “outperform” rating and a $1,100.00 target price on the stock. BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Citigroup began coverage on Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. Finally, Truist Financial boosted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $986.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.